

## Medicare: Medical Part B Step Therapy Criteria

| Drug Class                                                           | Non-Preferred Product(s)                                                                                                                 | Preferred Product(s)                                                                        |
|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| <b>Autoimmune Infused<br/>Infliximab</b>                             | Infliximab (J1745)<br>Remicade (J1745)                                                                                                   | Avsola (Q5121)<br>Inflectra (Q5103)<br>Renflexis (Q5104)                                    |
| <b>Autoimmune Infused/Other</b>                                      | Actemra (J3262, J3490, J3590)<br>Cimzia (J0717)<br>Ilumya (J3245)<br>Orencia (J0129)<br>Skyrizi (J2327, J3590)<br>Stelara (J3357, J3358) | Entyvio (J3380)<br>Simponi Aria (J1602)                                                     |
| <b>Avastin/Biosimilars<br/>(Oncology)</b>                            | Alymsys (Q5126)<br>Avastin (J9035)<br>Vegzelma (Q5129)                                                                                   | Mvasi (Q5107)<br>Zirabev (Q5118)                                                            |
| <b>Hematologic, Erythropoiesis -<br/>Stimulating Agents (ESA)</b>    | Epogen (J0885, Q4081)<br>Mircera (J0887, J0888)<br>Procrit (J0885, Q4081)                                                                | Aranesp (J0881, J0882)<br>Retacrit (Q5105, Q5106)                                           |
| <b>Hematologic, Colony<br/>Stimulating Factors – Long<br/>Acting</b> | Fylnetra (Q5130)<br>Neulasta (J2506)<br>Nyvepria (Q5122)<br>Rolvedon (J1449)<br>Stimufend (Q5127)<br>Udenyca (Q5111)                     | Fulphila (Q5108)<br>Ziextenzo (Q5120)                                                       |
| <b>Hematopoietic Agents - Iron</b>                                   | Feraheme (Q0138)<br>Ferumoxytol (Q0138)<br>Injectafer (J1439)<br>Monoferric (J1437)                                                      | Ferrlecit (J2916)<br>Infed (J1750)<br>Sodium Ferric Gluconate<br>(J2916)<br>Venofer (J1756) |
| <b>Lysosomal Storage Disorders<br/>(Gaucher Disease)</b>             | VPRIV (J3385)                                                                                                                            | Cerezyme (J1786)<br>Elelyso (J3060)                                                         |
| <b>Multiple Sclerosis (Infused)</b>                                  | Briumvi (J2329)<br>Lemtrada (J0202)                                                                                                      | Ocrevus (J2350)<br>Tysabri (J2323)                                                          |

| <b>Drug Class</b>                                                   | <b>Non-Preferred Product(s)</b>                                                                                                                                                                            | <b>Preferred Product(s)</b>                             |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
| <b>Osteoarthritis,<br/>Viscosupplements – Multi<br/>Injections</b>  | Euflexxa (J7323)<br>Gelsyn- 3 (J7328)<br>Genvisc 850 (J7320)<br>Hyalgan (J7321)<br>Hymovis (J7322)<br>Supartz FX (J73210)<br>Synojoynt (J7331)<br>Triluron (J7332)<br>Trivisc (J7329)<br>Visco – 3 (J7321) | Orthovisc (J7324)<br>Synvisc (J7325)                    |
| <b>Osteoarthritis,<br/>Viscosupplements – Single<br/>Injections</b> | Gel – One (J7326)<br>Monovisc (7327)                                                                                                                                                                       | Durolane (J7318)<br>Synvisc One (J7325)                 |
| <b>Osteoporosis – Bone Density</b>                                  | Evenity (J3111)<br>Reclast (J3489)                                                                                                                                                                         | Prolia (C9272, J0897)<br>Zoledronic Acid (J3489)        |
| <b>Rituximab</b>                                                    | Riabni (Q5123)<br>Rituxan (J9312)<br>Rituxan Hycela (J9311)                                                                                                                                                | Ruxience (Q5119)<br>Truxima (Q5115)                     |
| <b>Trastuzumab</b>                                                  | Herceptin (J9355)<br>Herceptin Hylecta (J9356)<br>Herzuma (Q5113)<br>Ontruzant (Q5112)                                                                                                                     | Kanjinti (Q5117)<br>Ogivri (Q5114)<br>Trazimera (Q5116) |

Molina Healthcare complies with applicable Federal civil rights laws and does not discriminate on the basis of race, ethnicity, national origin, religion, gender, sex, age, mental or physical disability, health status, receipt of healthcare, claims experience, medical history, genetic information, evidence of insurability, geographic location.

<https://www.molinahealthcare.com/members/common/en-US/multi-language-taglines.aspx>

Y0050\_24\_3668\_LRPtBDrgStThrpy\_C